

CITATION REPORT

List of articles citing

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501

DOI: 10.1007/s12325-019-00979-6
Advances in Therapy, 2019, 36, 1833-1850.

Source: <https://exaly.com/paper-pdf/73100986/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
16	IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. <i>Lancet Rheumatology</i> , 2019 , 1, e35-e43	14.2	4
15	Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 1019-1037	5.5	2
14	Biologic therapies for the treatment of hidradenitis suppurativa. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 621-633	5.4	5
13	Challenges for biosimilars: focus on rheumatoid arthritis. <i>Critical Reviews in Biotechnology</i> , 2021 , 41, 1219-123	4.3	4
12	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211031420	4.7	3
11	Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis. <i>Current Drug Targets</i> , 2021 , 22, 803-815	3	0
10	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4323-4333	3.8	6
9	A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1099-1102	2.5	3
8	Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre. <i>Australasian Journal of Dermatology</i> , 2021 , 62, e431-e432	1.3	1
7	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021 , 11, 10368	4.9	6
6	Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17. <i>Advances in Therapy</i> , 2021 , 38, 5609-5622	4.1	3
5	Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. <i>Advances in Therapy</i> , 2021 , 1	4.1	1
4	Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK Modeling.. <i>Clinical Therapeutics</i> , 2022 ,	3.5	
3	A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006).. <i>Current Medical Research and Opinion</i> , 2022 , 1-23	2.5	
2	Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.. <i>Expert Review of Clinical Immunology</i> , 2022 , 1-9	5.1	0
1	The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study. <i>Rheumatology and Therapy</i> ,	4.4	0